DLA Piper advises Phatisa on its exit from animal vaccine producer Deltamune

DLA Piper has advised Phatisa on its exit from Deltamune, a leading South African animal vaccine producer. Phatisa's interest was acquired by Vaxxinova, a Dutch animal health company. DLA Piper had advised Phatisa's initial investment into Deltamune in 2022.

The successful exit underscores the growing importance of African-led innovation in addressing global challenges such as Zoonotic diseases and pandemic preparedness. It also marks a significant milestone in the evolution of veterinary science and vaccine accessibility in emerging markets.

Phatisa is a leading African private equity fund manager focused on the food value chain, combining strong financial returns with meaningful social impact across the continent.

A multi-disciplinary team from DLA Piper's Johannesburg office worked on the transaction led by Corporate director Peter Bradshaw. He was supported by directors Andrew Lewis (Tax) and Werner Rysbergen (Lit&Reg), senior associate Byron Bromham, associate Shannon de Vries, and associate Nicole Sentoo.

Peter Bradshaw, director, commented “This transaction will strengthen Africa's capabilities to respond effectively to animal health threats. We are proud to have worked on this transaction that underscores the strength of local production capabilities to deliver global outcomes and underlines the strength of our longstanding relationship with Phatisa in supporting impactful investments across the continent.”

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, is number 1 across Africa and the Middle East by M&A deal volume for two years, according to Mergermarket, and number one in M&A in combined global deal volume according to PitchBook.